|
Market Closed -
Nasdaq
16:00:00 2026-09-21 EDT
|
5-day change | 1st Jan Change | ||
| 4.160 USD | +0.97% |
|
-6.31% | -13.87% |
Company Valuation: Relmada Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 624.7 | 105 | 124.6 | 15.69 | 354.2 | 443.7 | - | - |
| Change | - | -83.18% | 18.62% | -87.41% | 2,157.41% | 25.28% | - | - |
| Enterprise Value (EV) | 580.2 | 99.65 | 120.5 | 15.69 | 354.2 | 443.7 | 443.7 | 443.7 |
| Change | - | -82.83% | 20.94% | -86.98% | 2,157.41% | 25.28% | 0% | 0% |
| P/E | -3.15x | -0.66x | -1.26x | -0.2x | -3.33x | -6.68x | -5.22x | -5.62x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | 0x | 0x | 0x | 0.1x | 0.1x | -0.2x | 0.78x |
| Capitalization / Revenue | - | - | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -6.33x | -4.75x | -4.16x |
| EV / FCF | - | - | - | - | -0x | -6.25x | -5.16x | -4.64x |
| FCF Yield | - | - | - | - | -12.9% | -16% | -19.4% | -21.6% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -7.16 | -5.3 | -3.28 | -2.65 | -1.45 | -0.6225 | -0.7975 | -0.74 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | - | - | - |
| EBITDA | -85.21 | -161.2 | - | - | -59.1 | - | - | - |
| EBIT 1 | -125.7 | -161.2 | -103.7 | -83.89 | -59.1 | -70.06 | -93.49 | -106.7 |
| Net income 1 | -125.8 | -157 | -98.79 | -79.98 | -57.39 | -66.35 | -94.92 | -106.7 |
| Net Debt | -44.44 | -5.396 | -4.092 | - | - | - | - | - |
| Reference price 2 | 22.530 | 3.490 | 4.140 | 0.520 | 4.830 | 4.160 | 4.160 | 4.160 |
| Nbr of stocks (in thousands) | 27,726 | 30,099 | 30,099 | 30,174 | 73,334 | 106,670 | - | - |
| Announcement Date | 3/23/22 | 3/23/23 | 3/19/24 | 3/27/25 | 3/19/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -6.62x | - | - | - | 439M | |
| 20.78x | 7.3x | 14.73x | 1.43% | 70.88B | |
| 48.85x | 9.38x | 29.23x | 0.04% | 62.49B | |
| 30.44x | 6.47x | 16.8x | -.--% | 26.34B | |
| -73.25x | 14.16x | -68.28x | -.--% | 26.21B | |
| -14.7x | 5.35x | -6.73x | -.--% | 24.13B | |
| 28.25x | 5.33x | 17.72x | -.--% | 20.72B | |
| 45.45x | 16.69x | 33.86x | 0.33% | 15.69B | |
| 18.03x | 5.37x | 12.55x | -.--% | 14.46B | |
| -15.41x | 3481.82x | -17.8x | -.--% | 14.24B | |
| Average | 8.18x | 394.65x | 3.56x | 0.2% | 27.56B | |
| Weighted average by Cap. | 15.93x | 188.28x | 7.95x | 0.4% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- RLMD Stock
- Valuation Relmada Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
